In­cyte ax­es JAK1 in­hibitor from pipeline two years af­ter a PhI­II flop crushed hopes

In the first few days of 2020, In­cyte re­port­ed that its JAK1 in­hibitor failed a Phase III study in first-line, acute graft vs host dis­ease. With the flop came a $2 bil­lion mar­ket cap era­sure.

This time around, In­cyte isn’t even com­plet­ing a study of the drug, known as itac­i­tinib, be­cause ef­fi­ca­cy da­ta from part of a Phase II/III study give the bio­phar­ma no signs of hope for a piv­otal suc­cess.

The GRAV­I­TAS-309 study was test­ing itac­i­tinib in pa­tients with treat­ment-naïve chron­ic GVHD, but the com­pa­ny de­cid­ed to scrap those plans, it re­vealed Tues­day in a quar­ter­ly earn­ings up­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER